AKEBIA THERAPEUTICAKEBIA THERAPEUTICAKEBIA THERAPEUTIC

AKEBIA THERAPEUTIC

No trades
See on Supercharts

Price target

6.050.000.00%
The 5 analysts offering 1 year price forecasts for AX9 have a max estimate of — and a min estimate of —.

Analyst rating

Based on 5 analysts giving stock ratings to AX9 in the past 3 months.

EPS

Reported
Estimate
Reported
Estimate
Surprise

Revenue

Reported
Estimate
Reported
Estimate
Surprise
Be warned

Frequently Asked Questions


AX9 EPS for the last quarter is 0.03 CHF despite the estimation of −0.03 CHF. In the next quarter EPS is expected to reach −0.02 CHF. Track more of AKEBIA THERAPEUTIC financials and stay on top of what is up with the company.
In the next quarter AKEBIA THERAPEUTIC revenue is expected to reach ‪39.10 M‬ CHF. Check out AKEBIA THERAPEUTIC revenue and earnings and make informed decisions.
According to analysts, AX9 price target is 6.05 CHF with a max estimate of 8.29 CHF and a min estimate of 4.97 CHF. Check if this forecast comes true in a year, meanwhile watch AKEBIA THERAPEUTIC stock price chart and keep track of the current situation with AX9 news and stock market news.
We've gathered opinions of 5 analysts rating AX9 stock in the past 3 months. Most of them backed up the strong buy trend, and after taking into account other opinions, the overall rating was calculated as strong buy. Note that it's not a trading advice — your own analysis is still required.